Amanda Silva Martins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amanda Silva Martins has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Anelise Baptista da Silva
Pontifical Catholic University of Rio Grande do Sul - PUCRS, School of Health and Life Sciences, Laboratory of Immunology and Microbiology, Porto Alegre, Brazil
1 shared publication - Ariane Baptista Monteiro
Serviço de Controle de Infecção, Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre 90610-001, RS, Brazil
1 shared publication - Carlos Alexandre Sanchez Ferreira
Affiliation Laboratório de Imunologia e Microbiologia, Escola de Ciências da Saúde e da Vida, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Rio Grande do Sul, Brazil
1 shared publication - Claudia Flores
Instituto Nacional de Controle de Qualidade em Saúde INCQS/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil
1 shared publication - Diego Rodrigues Falci
Infectious Diseases Service, Hospital de Clínicas de Porto Alegre , Porto Alegre
1 shared publication - Gabriel Lemos Buss
Laboratório de Imunologia e Microbiologia, Escola de Ciências da Saúde e da Vida, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre 90619-900, RS, Brazil
1 shared publication
Latest Publications
- Open Access
- 10 November 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (11) , 1140
Widespread Distribution of Carbapenem-Resistant Klebsiella spp. in Clinical and Environmental Settings
Background/Objectives: Klebsiella spp., particularly K. pneumoniae, are major opportunistic pathogens in healthcare settings driven by carbapenemase- and ESBL-producing strains. We assessed antimicrobial resistance and biofilm formation abilities in Klebsiella spp. from a Brazilian tertiary hospital and related environments and characterized capsular types. Methods: Over six months (July–December 2023), 303 carbapenem-resistant Klebsiella spp. were collected from clinical specimens (n = 198), ICU/non-ICU surfaces (n = 79), hospital sewage (n = 22), and stream water (n = 4). Species were identified by MALDI-TOF. Susceptibility testing covered eight antibiotic classes, focusing on carbapenems and polymyxin B. Biofilm formation was quantified by crystal violet, and capsular typing used wzi/K-locus approaches. Results: Most isolates (70.95%) had meropenem MICs ≥ 128 μg/mL, while 77.6% (n = 235) remained susceptible to polymyxin B. Resistance profiles largely consisted of extensive drug resistance (95.4%), with 1.3% exhibiting pandrug resistance, including isolates from bed rails. Biofilm formation was detected in 96.7% of isolates, mainly weak (67.6%) or moderate (28%), with 4.4% being strong producers. Among the Klebsiella isolates analyzed, 21 K types were identified with an uneven distribution dominated by K64, followed by K24, K173, and K50. K75 was the only K type detected across all sources—clinical isolates, bed-rail surfaces (non-ICU), wastewater, and fluvial water. Conclusions: Carbapenem-resistant Klebsiella spp. exhibited widespread resistance, with residual susceptibility to aminoglycosides, ceftazidime–avibactam, and polymyxins. Environmental reservoirs—hospital surfaces, sewage, and stream water—harbored resistant biofilm producers, reinforcing their role in persistence and dissemination. K-typing revealed concentrated distribution (predominantly K64) and cross-source K75. These findings underscore the urgency of integrated strategies combining molecular surveillance, antimicrobial stewardship, and environmental control.
- 10 November 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (11) , 1140
Open AccessWidespread Distribution of Carbapenem-Resistant Klebsiella spp. in Clinical and Environmental Settings
Background/Objectives: Klebsiella spp., particularly K. pneumoniae, are major opportunistic pathogens in healthcare settings driven by carbapenemase- and ESBL-producing strains. We assessed antimicrobial resistance and biofilm formation abilities in Klebsiella spp. from a Brazilian tertiary hospital and related environments and characterized capsular types. Methods: Over six months (July–December 2023), 303 carbapenem-resistant Klebsiella spp. were collected from clinical specimens (n = 198), ICU/non-ICU surfaces (n = 79), hospital sewage (n = 22), and stream water (n = 4). Species were identified by MALDI-TOF. Susceptibility testing covered eight antibiotic classes, focusing on carbapenems and polymyxin B. Biofilm formation was quantified by crystal violet, and capsular typing used wzi/K-locus approaches. Results: Most isolates (70.95%) had meropenem MICs ≥ 128 μg/mL, while 77.6% (n = 235) remained susceptible to polymyxin B. Resistance profiles largely consisted of extensive drug resistance (95.4%), with 1.3% exhibiting pandrug resistance, including isolates from bed rails. Biofilm formation was detected in 96.7% of isolates, mainly weak (67.6%) or moderate (28%), with 4.4% being strong producers. Among the Klebsiella isolates analyzed, 21 K types were identified with an uneven distribution dominated by K64, followed by K24, K173, and K50. K75 was the only K type detected across all sources—clinical isolates, bed-rail surfaces (non-ICU), wastewater, and fluvial water. Conclusions: Carbapenem-resistant Klebsiella spp. exhibited widespread resistance, with residual susceptibility to aminoglycosides, ceftazidime–avibactam, and polymyxins. Environmental reservoirs—hospital surfaces, sewage, and stream water—harbored resistant biofilm producers, reinforcing their role in persistence and dissemination. K-typing revealed concentrated distribution (predominantly K64) and cross-source K75. These findings underscore the urgency of integrated strategies combining molecular surveillance, antimicrobial stewardship, and environmental control.